Atlas Trials

Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Clinical trial NCT01340833 · COMPLETED

Trial details

NCT number
NCT01340833
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Cancer
Start date
2011-06-08
Primary completion
2011-09-12
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.